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a b s t r a c t
Several novel melatonin receptor agonists, in addition to various formulations of melatonin itself, are
either available or in development for the treatment of insomnia. Melatonin is thought to exert its effects
principally through two high afﬁnity, G-protein coupled receptors, MT1 and MT2, though it is not known
which subtype is responsible for the sleep-promoting action. The present study used radiotelemetry
to record EEG and EMG in un-restrained freely moving rats to monitor the sleep-wake behaviour and
examined the acute sleep-promoting activity of an MT2 receptor subtype selective melatonin analog,
IIK7. IIK7 is a full agonist at the MT2 receptor subtype but a partial agonist at the MT1 receptor andIK7
elatonin agonist
has ∼90-fold higher afﬁnity for MT2 than MT1. Like melatonin, IIK7 (10mg/kg i.p.) signiﬁcantly reduced
NREM sleep onset latency and transiently increased the time spent in NREM sleep, but did not alter REM
sleep latency or the amount of REM sleep. An analysis of the EEG power spectrum showed no change
in delta (1–4Hz) or theta activity (5–8Hz) following IIK7 administration. Core body temperature was
slightly decreased (∼0.3 ◦C) by IIK7 compared to vehicle-treated rats. The acute and transient changes
imic
tivatiin the sleep-wake cycle m
activity is mediated by ac
elatonin synthesis in the pineal gland is controlled by the mas-
er circadian oscillator in the suprachiasmatic nucleus (SCN) which
rives the release of noradrenaline from the sympathetic, auto-
omic neurones which innervate the gland. This multisynaptic
eural pathway from the SCN to the pineal is activated each night
n darkness resulting in an increase in melatonin synthesis which
enerates the dramatic diurnal rhythm in plasma melatonin seen
n mammals [13]. The daily rhythm of melatonin plays an essential
ole in regulating the various changes in physiology which occur in
hotoperiodic (seasonal) mammals [14]. In mammals, melatonin
ay also play a role in organising circadian physiology; melatonin
eceptors are expressed in the SCN [7] and, with appropriate tim-
ng of administration, activation of these receptors can re-entrain
he circadian clock both in vivo [19] and in vitro [20]. Indeed, mela-
onin administration can phase-shift and entrain human circadian
hythms [2,3], and the hormone has found increasing use as a treat-
ent for sleep disorders. In fact, a prolonged release formulation
f melatonin [Circadin®] and a melatonin agonist [Rozerem®] have
een introduced recently for the treatment of insomnia [24,16], and
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oi:10.1016/j.neulet.2009.04.005the changes seen with melatonin and suggest that its sleep-promoting
on of the MT2 receptor subtype.
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othermelatonin agonists or formulations are indevelopment [11]. A
recent clinical trial of anothermelatonin agonist (tasimelteon, VEC-
162) reportedbeneﬁcial effectsonsleep latencyandmaintenance in
healthy volunteers whose sleep was disrupted by a 5-h advance of
the sleep-wake schedule [18]. Melatonin is likely effective because
of both an acute sleep-promoting action and the ability to phase-
shift circadian rhythms. Melatonin’s actions are mediated by two
G-protein coupled receptor subtypes, MT1 and MT2 receptors; evi-
dence suggests that the phase-shifting response is mediated by the
MT2 receptor subtype [6], but it is not known which receptor sub-
type is involved in the acute sleep-promoting action. Themelatonin
analogs tested for their effects on sleep so far have no selectivity for
either subtype [9,18,23]. The present study investigated the acute
effects of anMT2-subtype speciﬁc agonist [8] on sleep in a ratmodel
previously shown to detect the acute sleep-promoting effects of
melatonin and a clinically available melatonin agonist, ramelteon
[9].
Adult male Sprague–Dawley rats (250–300g, Harlan, UK) were
housed under a 12h:12h light–dark cycle (lights on 07:00–19:00h)
at an ambient temperature of 21±1 ◦C. Food and water were avail-
able ab libitum. All procedures were in accordance with the UK
Animal Scientiﬁc Procedures Act (1986).
Rats were anaesthetized with ketamine (75mg/kg i.p.; Fort
Dodge Animal Health Ltd., Southampton, UK) combined with
medetomidine (0.5mg/kg i.p.; Pﬁzer, Sandwich, UK) and implanted
with a radiotelemetry transmitter (Model TL11M2-F40-EET; Data
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ciences International, St. Paul, USA) into the peritoneal cavity [9].
pair of leads from the transmitter recorded cortical EEG via stain-
ess steel screws placed on the skull (2mm anterior to lambda on
he right hand side, 2mm anterior to bregma on the left hand side)
ith the screw tip resting on the dura. Two leads recorded EMG
rom the musculus cervicoauricularis. Core body temperature (Tc)
nd locomotor activity data were obtained from the body of the
adiotransmitter. Recovery from surgery was monitored by exam-
nation of the diurnal rhythm in Tc; restoration of a robust diurnal
hythm in Tc (at least 2 weeks) was required before implanted rats
ere used in an experiment.
EEG, EMG, Tc and locomotor activity data were transmitted
o a Data Sciences radio receiver (RPC-1) underneath each rat
age, then routed to a PC running DSI Dataquest Gold acquisition
oftware. EEG and EMG data were continuously sampled at 500Hz,
ith a 100Hz ﬁlter cut-off, band-pass ﬁltered (0.5–35Hz for EEG
nd 80–120Hz for EMG) and then used to identify vigilance states.
leep/wake stages were scored as wake (W), NREM (non-rapid
ye movement) sleep and REM (rapid eye movement) sleep for
ach 10 s epoch using a semi-automated approach as described
reviously [9]. Brieﬂy, an initial automated step using SleepSign®
oftware (Kissei Comtec, Nagano, Japan) was followed by a review
f all epochs by an experienced sleep scorer to eliminate errors in
he assignment of W, NREM and REM stages using the EEG/EMG
riteria deﬁned previously [15]. NREM sleep onset latency was
eﬁned as the time from injection to the occurrence of 12 consec-
tive NREM epochs, and REM sleep onset latency as the time to
he occurrence of 3 consecutive REM epochs. EEG power spectra
or NREM and REM epochs were analysed ofﬂine using Fast Fourier
ransformation (512 point, Hanningwindow, 0.5–20Hzwith 0.5Hz
esolution using SleepSign®). Rats were injected (i.p.) with the MT2
elatonin receptor agonist, IIK7 (10mg/kg; dissolved in 2% DMSO,
hen diluted with 45%, w/v (2-hydroxypropyl)-beta-cyclodextrin)
r vehicle (drug diluent). Treatments were administered in a
ully balanced cross-over design with all rats receiving both
rug and vehicle, with at least 1 week between treatments.
rug or vehicle was administered at 24:00h (5h after D onset).
IK7 (N-butanoyl-2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-
ig. 1. Effect of the MT2 selective agonist IIK7 on sleep in the rat. Rats housed under a 1
10mg/kg) at 24:00h in a balanced cross-over design. (A) NREM sleep onset latency. (B) N
leep onset latency. (D) REM sleep duration in the 2h before treatment, and the 4h after in
ean± S.E.M. of data from 6 rats. *p<0.05, signiﬁcantly different from vehicle-treated rate Letters 457 (2009) 93–96
yl)ethanamine) was synthesized at University College London, UK
[8].
IIK7 is one of a series of tetracyclic analogues of melatonin
synthesized to explore the role of the indole nitrogen region of
melatonin in the binding of the ligand to the melatonin receptor
[8]. Information on these analogs, and other structure-activity data
[25], indicate that the binding pocket of the MT2 receptor subtype
is less stringent in the indole nitrogen/2-position ofmelatonin than
the MT1 receptor subtype. As a result, compounds like IIK7 can
be readily accommodated by the MT2 receptor but show weaker
afﬁnity for the MT1 receptor subtype. IIK7 has a 90-fold selec-
tivity for MT2 (compared to MT1) in radioligand binding assays,
with an MT2 receptor subtype afﬁnity (pKi 0.05nM) about 6-fold
higher thanmelatonin itself (0.33nM) [22]. InNIH3T3cells express-
ing the recombinant melatonin receptor subtypes, IIK7 is a full
agonist at the MT2 receptor, but a less potent, partial agonist on
the MT1 subtype (intrinsic activity ∼60% that of melatonin) [8].
In a well-established model of melatonin action, the Xenopus lae-
vis melanophore aggregation assay [21], IIK7 is a full agonist with
a potency (EC50 4.2±1.4nM) 30-fold less than melatonin (EC50
141±20pM) (Sugden and Bocianowska, unpublished data).
In the sleep studies, strict criteria were adopted to deﬁne NREM
sleep onset latency (120 s of continuous NREM sleep) and a consis-
tent routinewasused for dosing inwhich ratswere left undisturbed
for 30–36h before treatment. Before the start of the experiment all
ratswere fully accommodated to i.p. injectionwhichwascompleted
rapidly with minimal stress. This protocol gave NREM sleep onset
latency values after vehicle injection which were very consistent,
with a SEM of ∼10–15% of the mean with 6 rats per group.
Though IIK7 dissolved readily in DMSO it precipitated from
solution when added to 0.9% (w/v) saline; higher percentages of
DMSO did not improve solubility. Finally, a stable solution of IIK7
for injection was made by dissolving the compound in DMSO
(ﬁnal concentration 2%, v/v) followed by dilution in 45% (w/v)
(2-hydroxypropyl)-beta-cyclodextrin in saline. Vehicle-treated
rats received 2% (v/v) DMSO/45% (w/v) (2-hydroxypropyl)-beta-
cyclodextrin in saline. NREM sleep onset and REM sleep onset
latencies after injection of this vehicle (Fig. 1) were some-
2h:12h L:D cycle (L on at 07:00h) were injected (i.p.) with either vehicle or IIK7
REM sleep duration in the 2h before treatment, and the 4h after injection. (C) REM
jection. Arrows indicate time of IIK7 or vehicle administration. Each bar represents
s.
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Fig. 2. Effect of IIK7 administration on (A) delta power in the EEG during NREM sleep, (B) theta power during REM sleep, and (C) core body temperature (◦C). All epochs
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bcored as NREM (during the ﬁrst 1h) or REM (during the ﬁrst 2h) after injection of v
.5 to 20Hz. For each rat, delta power (power in the delta range, 1–4Hz) during NR
EG power in all of the NREM or REM epochs analysed, respectively. Mean delta (A)
s every 5min from 20:00h to 04:00h. Mean data for each hour of recording was a
hat greater than after administration of the vehicle (1%, v/v
MSO/saline) used in earlier experiments [9]. These changes seem
nlikely to be caused by the increased percentage of DMSO in the
ehicle (2%, v/v vs. 1%, v/v) considering that DMSO up to 10% (v/v)
n saline was reported to have no effect on sleep [5] and there-
ore may be related to the cyclodextrin vehicle. Nevertheless, even
hough the NREM sleep onset latency in this series of experimen-
al rats was relatively high after vehicle treatment (72.5±8.5min),
IK7 signiﬁcantly reduced NREM sleep onset time (44.8±7.9min,
= 0.027, n=6; Fig. 1A). REM sleep onset latency was not altered by
IK7 (vehicle, 128.5±16.8min; IIK7, 132.1±21.0min, n=6; Fig. 1C).
he amount of time spent in NREM sleep after IIK7 was increased
50% during the ﬁrst hour after dosing (vehicle, 3.9±0.9min; IIK7,
.7±2.3min, p<0.05, n=6) reﬂecting the decrease in NREM onset
ime. No signiﬁcant changes in NREM sleep were apparent during
he second, third or fourth hours after IIK7 administration (Fig. 1B),
nd REM sleep time was not altered by IIK7 (Fig. 1D).
An analysis of the EEG power spectrum in all NREM and REM
leep epochs for the ﬁrst 60min (NREM) or 90min (REM) after
osing with vehicle or IIK7 revealed no change in the power spec-
rum. Fig. 2A shows the mean power in delta (1–4Hz) in IIK7- and
ehicle-treated rats during NREM sleep (expressed as a percentage
f the total power). Power in the delta band, also referred to as slow
ave activity (SWA), is enhanced by sleep-promoting drugs such
s zolpidem [1], and is also increased during the rebound NREM
ollowing sleep deprivation and is thought to represent a quantita-
ive estimate of the homeostatic sleep process [10]. Previously, we
ave shown that neither melatonin nor ramelteon, administered
o rats by i.p. injection at the same dose as IIK7, altered the NREM
leep EEG power spectrum [9]. IIK7, like melatonin and ramelteon
9], also failed to alter EEG power in the theta band (5–8Hz) during
EM sleep. IIK7 produced a small reduction in core body tempera-
ure (Tc) after administration (Fig. 2C). During the 4h period before
reatment there was no difference in Tc, between the two groups.
fter treatment,Tc of bothgroups increased transiently (ZT17–18h)
ut the rise in Tc after IIK7 injection was only ∼50% of that seen
ith vehicle. During the second hour of treatment (ZT 18–19h) Tc
ell in both groups but the fall in the group treated with IIK7 (Tc
0.49 ◦C) was over twice as large as that measured in the vehicle-
reatedgroup (Tc −0.24 ◦C). The fall inTc slowedand thenbegan to
everse in both treatment groups during the third and fourth hour
f treatment. A fall in Tc is commonly seen after administration of
ypnotic drugs.This is the ﬁrst study to investigate the melatonin receptor sub-
ype involved in the acute sleep-promoting action of melatonin
sing a selective melatonin ligand. To date, IIK7 is one of only
ery few subtype selective melatonin receptor agonists which have
een characterised in vitro using both radioligand binding assaysor IIK7 were analysed using the Fast Fourier Transform function of SleepSign from
ep and theta power (5–8Hz) was calculated and expressed as a percentage of total
eta (B) power± S.E.M. data is shown. (C) Core body temperature was measured for
ed and the mean± S.E.M. of these values for all 6 rats is shown.
to obtain receptor afﬁnity data and cellular assays to determine
functional activity on each receptor subtype. In radioligand bind-
ing experiments on recombinant cloned receptor subtypes, IIK7 has
∼90-fold greater afﬁnity for the MT2 subtype than the MT1 sub-
type, and has slightly greater MT2 receptor subtype afﬁnity (6-fold
greater) than melatonin [8]. It also acts as a full agonist at the MT2
receptor when tested on cells (inhibition of forskolin-stimulated
cyclic AMP in cells expressing recombinant MT2 receptors) with
similar potency (3-fold greater) to melatonin, while at the MT1
receptor potency is 30-fold weaker and it has only partial agonist
activity. This afﬁnity and potency data led us to use IIK7 at a dose
(10mg/kg i.p.) which is the same as the dose of melatonin (and
ramelteon) that we have shown previously signiﬁcantly reduced
NREM latency and increased NREM sleep duration in the ﬁrst hour
after administration [9]. Lower doses ofmelatonin (e.g. 3mg/kg i.p.)
or ramelteon (1mg/kg i.p.) have no signiﬁcant effect onNREMsleep
onset latencyorNREMduration after treatment [Fisher andSugden,
unpublished data]. Though the pharmacokinetics and metabolism
of IIK7areunknown, theacute effects of IIK7were theprimary focus
of this study, and indeed IIK7, likemelatonin, produced a signiﬁcant
decrease in NREM sleep onset latency with a signiﬁcant, though
brief, increase in NREM duration after administration. No change
in REM onset latency, REM duration, delta activity during NREM
sleep or theta power in the EEG during REM sleep were observed,
which again is consistent with the effects seen after administra-
tion of melatonin or the non-subtype selective agonist, ramelteon
[9]. This marked similarity in the proﬁle of sleep changes suggests
that IIK7 mimics the effect of melatonin administration on sleep.
Our earlier work on the sleep-promoting effect of melatonin and
ramelteon [9] did not measure Tc, but others [12] have reported
that administration of similar doses of melatonin during the night
does produce a small fall in Tc similar to that seen with IIK7. The
selectivity of IIK7 for the MT2 receptor suggests that this receptor
is the subtype which mediates the acute sleep-promoting action
of melatonin. A meeting abstract [17] reported that subcutaneous
administration of another selectiveMT2 receptor agonist (UCM765)
to rats reduced NREM latency and increased NREM sleep duration.
However, UCM765 also delayed REM sleep onset as effectively as
diazepam suggesting that this melatonin analog may act on addi-
tional receptors.
This study has shown that IIK7, an MT2 subtype selective ago-
nist exhibits an acute sleep-promoting action in the rat which is
very similar to that seen after administration of melatonin, sug-
gesting that an MT2 melatonin receptor subtype mediates the
acute hypnotic effect. The data highlight that the sleep-promoting
effects observed after the administration of melatonin and
related analogues are distinct from those produced by commonly
used sedative-hypnotics. These include the non-benzodiazepine
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olpidem, which, in contrast to melatoninergic compounds, alters
he EEG power spectra of NREM sleep and can inhibit REM sleep
1]. Further studies will be necessary to conﬁrm the role of the
T2 receptor subtype in this response including the use of MT2-
ubtype selective antagonists. Although a few antagonists with
T2-selectivity are currently available [4], the afﬁnity of these com-
ounds is lower than the afﬁnity of melatonin itself which may
ose practical difﬁculties in delivering sufﬁciently high doses of
ntagonists to effectively antagonise melatonin.
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